Skip to main content
Premium Trial:

Request an Annual Quote

AltheaDx NeuroIDgenetix Test Expansion

AltheaDx has expanded NeuroIDgenetix, the neuropsychiatric component of its IDgenetix pharmacogenetics (PGx) testing portfolio. The panel now includes PGx testing for medication used to treat both bipolar disorder and seizure disorder. The addition of these two new offerings means the panel now includes a total of six tests for neuropsychiatric disorders (depression, anxiety, bipolar disorder, ADHD, psychosis, and seizure disorder) and four tests for pain (arthritis, migraine, musculoskeletal pain, and neuropathic pain). The expanded panel evaluates a total of 128 FDA-approved neuropsychiatric and pain medications, including mood stabilizers for bipolar disorder and a variety of anticonvulsant medications used to treat seizure disorders. The panel also analyzes 15 clinically validated genes, including those involved in drug metabolism and those that influence individual response to a variety of different medications.